Evidence map›Paper›PMID 34439209›Full record

ArticleCancers2021

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer.

Edoardo Francini, Fang-Shu Ou, Justin Rhoades, Eric G Wolfe, Edward P O'Connor, Gavin Ha, Gregory Gydush, Kaitlin M Kelleher, Rupal S Bhatt, Steven P Balk and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Edoardo FranciniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-4270-7023
Fang-Shu OuDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-1267-8735
Justin RhoadesEli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Eric G WolfeDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
Edward P O'ConnorDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Gavin HaDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Gregory GydushEli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Kaitlin M KelleherDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Rupal S BhattBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Steven P BalkBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0002-4546-7371
Christopher J SweeneyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Viktor A AdalsteinssonEli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Mary-Ellen TaplinDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Atish D ChoudhuryDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-9344-6631

Funding

Roche Italia "Fondazione Roche per la Ricerca Indipendente" grant
6 · The paper itself

Abstract

There are no biomarkers predictive of resistance to docetaxel or cabazitaxel validated for patients with metastatic castration-resistant prostate cancer (mCRPC). We assessed the association between

Indexed as

biomarkerscell-free DNAmetastatic castration-resistant prostate cancertaxanes

Identifiers

PMID34439209
PMCPMC8391478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.